How can we predict immunogenicity earlier in biotherapeutics?
As experts strive to develop successful therapeutics for increasingly personalized patient populations, effective collaboration and pre-competitive cooperation can help them predict immunogenicity with greater accuracy.
Industry professionals need solutions that allow reproducibility of experimental results, enforce data integrity, and offer work environments that are easily accessible to people with a wide range of expertise. Equipped with standards and protocols that consider virtual and real experiments to be equal partners in the development of biotherapeutics, scientists can make better-informed decisions, identify potential immune responses earlier, and accelerate new products to market.